摘要
自体造血干细胞移植常用于治疗多发性骨髓瘤、恶性淋巴瘤、低危组急性粒细胞白血病,适应证目前已经拓展至某些遗传性血液系统疾病以及自身免疫性疾病。自体造血干细胞的动员、采集、冻存及复苏等质量控制对于移植的成功率非常重要,未来针对造血干细胞质量控制相关的研究会进一步的深入和优化。现阶段,中国的自体造血干细胞移植数量较欧美仍较少,但随着各移植中心技术的成熟,移植医生对移植患者年龄的主动拓展、对移植前化疗方案的优化更新,预处理方案的选择和优化,以及移植后的系统管理,自体造血干细胞的成功率和安全性将得到进一步的提高。基于此,我们推测中国自体造血干细胞移植未来的数量和质量将会大幅度的提升,而与此相匹配的相关科学问题将成为未来临床科研工作者面临的挑战和机遇。
Autologous hematopoietic stem cell transplantation(Auto-HSCT)is commonly used in multiple myeloma(MM),malignant lymphoma,and low-risk acute myeloid leukemia(AML),as well as some autoimmune disorders and inherited blood system diseases.The quality control such as mobilization,collection,cryopreservation and resuscitation of hematopoietic stem cell(HSCT)plays a critical role in successful engraftment of auto-HSCT,thus it is important for the success rate of transplantation.Future research on quality control of hematopoietic stem cells will be further in-depth and optimized.The total number of auto-HSCT remains small in China compared with USA and European countries at present.However,physicians have actively expanded auto-HSCT for elderly candidates,optimized chemotherapy regimens and chemotherapy courses,renewed conditioning regimens,and systematically managed complications post auto-HSCT.Therefore,these measures largely improved the effects and safety of auto-HSCT with the maturity of transplant center technology.Based on this,we speculate that the quality and quantity of auto-HSCT in China will have a marked increment and improvement.Accordingly,the corresponding academic researches on auto-HSCT will emerge as an opportunity and challenges for physicians and researchers in the future.
作者
闫金松
Yan Jinsong(Department of Hematology,Second Hospital of Dalian Medical University,Dalian 116027,Liaoning,China)
出处
《中国医学前沿杂志（电子版）》
CSCD
北大核心
2024年第9期12-15,I0002,共5页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
自体造血干细胞移植
血液肿瘤
质量控制
干细胞动员
预处理
Autologous hematopoietic stem cell transplantation
Hematological malignancy
Quality control
Stem cell mobilization
Conditioning
